Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
Bioequity EuropeBioequity Europe
Not Confirmed
Not Confirmed
04-06 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Arvo
Not Confirmed
Contact SupplierArvo
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Bioequity EuropeBioequity Europe
Industry Trade Show
Not Confirmed
04-06 May, 2026
Digital content
NEWS #PharmaBuzz
22 Apr 2016
// CPHI ONLINE
http://cphi-online.com/3m-unveils-intelligent-inhaler-designed-to-help-news040176.html
14 Mar 2015
// Eric Palmer FIERCE PHARMA
http://www.fiercepharma.com/story/jj-gsk-legal-dust-over-flonase-allergy-claims/2015-03-13
Drugs in Development
Details:
Nicotine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tobacco Use Disorder.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: GSK | McNeil AB
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 04, 2015
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK | McNeil AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy
Details : Nicotine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tobacco Use Disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 04, 2015
Details:
Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Methylphenidate
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Recipient: University of Utah
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 13, 2014
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Recipient : University of Utah
Deal Size : Inapplicable
Deal Type : Inapplicable
OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD
Details : Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 13, 2014
Details:
JNJ-10450232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain.
Lead Product(s): JNJ-10450232
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2014
A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine
Details : JNJ-10450232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2014
Details:
Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Toothache.
Lead Product(s): Paracetamol
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2013
Lead Product(s) : Paracetamol
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Long-Acting Acetaminophen in Postoperative Dental Pain
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Toothache.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2013
Details:
Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.
Lead Product(s): Cetirizine
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Recipient: California Allergy and Asthma Medical Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 01, 2013
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : California Allergy and Asthma Medical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Bronchodilation Effects of Cetirizine
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2013
Details:
Nicotine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tobacco Use Disorder.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: McNeil AB | GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2011
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : McNeil AB | GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking
Details : Nicotine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tobacco Use Disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 15, 2011
Details:
Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2010
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2010
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
McNeil Consumer Health is a supplier offers 3 products (APIs, Excipients or Intermediates).
Find Nicotine bulk with DMF offered by McNeil Consumer Health
Find Nicotine bulk offered by McNeil Consumer Health
Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN STOUFFVILLE, ONTARIO, CANADA. bulk offered by McNeil Consumer Health
Share 
